Administering erythropoietin stimulating agents (ESAs) to patients with anemia also augments, in peripheral blood, the proportion of young RBCs, which have a lower rate of glycosylation than do old RBCs, thereby altering glycosylated hemoglobin formation25. This evidence concerns the gene EPO and anemia.